8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 27, 2026·SEC
Material company update
Mar 3, 2026·SEC
Cigna Corporation(CI)Earnings, Financials & Key Ratios
CI•NYSE•Insurance & Managed Care
$275.66
$72.68B mkt cap·12.4× P/E·Price updated May 6, 2026
AboutThe Cigna Group provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care delivery and management, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans to on and off the public exchanges; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. The company also offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. It distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.Show more
- Revenue$274.95B+11.3%
- Combined Ratio96.68%+0.5%
- Net Income$5.96B+73.5%
- Return on Equity14.33%+82.8%
- Medical Cost Ratio90.55%+1.2%
- Operating Margin3.32%-12.9%
- Net Margin2.17%+55.9%
- ROA3.8%+70.6%
- Equity / Assets26.52%+0.2%
- Book Value per Share157.45+8.1%
- Tangible BV/Share-118.86+4.8%
- Debt/Equity0.75-3.1%
CI Key Insights
Cigna Corporation (CI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 8/9
- ✓Healthy dividend yield of 2.2%
- ✓Share count reduced 6.1% through buybacks
✗Weaknesses
- ✗High loss ratio of 90.5%
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CI Price & Volume
Cigna Corporation (CI) stock price & volume — 10-year historical chart
Loading chart...
CI Growth Metrics
Cigna Corporation (CI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years21.92%
5 Years11.38%
3 Years15.06%
TTM8.84%
Profit CAGR
10 Years11.02%
5 Years-6.77%
3 Years-3.86%
TTM24.91%
EPS CAGR
10 Years10.68%
5 Years-0.7%
3 Years1.17%
TTM30.56%
Return on Capital
10 Years7.39%
5 Years8.3%
3 Years8.91%
Last Year9.15%
CI Recent Earnings
Cigna Corporation (CI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
Apr 30, 2026EPS
$7.79
Est $7.60
+2.5%
Revenue
$68.5B
Est $66.3B
+3.3%
Q1 2026
Feb 5, 2026EPS
$8.08
Est $7.88
+2.5%
Revenue
$72.5B
Est $70.3B
+3.1%
Q4 2025
Oct 30, 2025EPS
$7.83
Est $7.64
+2.5%
Revenue
$69.7B
Est $67.6B
+3.2%
Q3 2025
Jul 31, 2025EPS
$7.20
Est $7.16
+0.6%
Revenue
$67.2B
Est $62.9B
+6.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $7.79vs $7.60+2.5% | $68.5Bvs $66.3B+3.3% |
| Q1 2026 | Feb 5, 2026 | $8.08vs $7.88+2.5% | $72.5Bvs $70.3B+3.1% |
| Q4 2025 | Oct 30, 2025 | $7.83vs $7.64+2.5% | $69.7Bvs $67.6B+3.2% |
| Q3 2025 | Jul 31, 2025 | $7.20vs $7.16+0.6% | $67.2Bvs $62.9B+6.9% |
Based on last 12 quarters of dataView full earnings history →
CI Peer Comparison
Cigna Corporation (CI) competitors in Vertically Integrated Payer-PBM Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 UNH | 330.28B | 363.87 | 27.50 | 11.81% | 2.68% | 11.54% | 4.87% | 0.77 |
 ELV | 80.15B | 369.07 | 14.69 | 12.62% | 2.62% | 11.92% | 3.96% | 0.75 |
 CVS | 102.56B | 80.69 | 58.05 | 7.85% | 0.44% | 2.35% | 7.61% | 1.24 |
 HUM | 28.76B | 239.53 | 24.34 | 10.06% | 0.82% | 6.17% | 1.3% | 0.73 |
 CNC | 26.15B | 52.97 | -3.89 | 19.44% | -3.25% | -28.6% | 16.52% | 0.94 |
 MOH | 10.01B | 192.17 | 21.54 | 11.75% | 0.42% | 4.44% | 0.97 | |
 ESNT | 5.87B | 60.17 | 8.78 | 12.03% | 53.73% | 12.25% | 14.57% | 0.09 |
 MCK | 98.11B | 801.01 | 31.14 | 16.22% | 1.09% | 5.33% |
Compare CI vs Peers
Cigna Corporation (CI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CI Income Statement
Cigna Corporation (CI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.81B | 48.65B | 153.57B | 160.4B | 174.07B | 180.52B | 195.26B | 247.12B | 274.95B | 277.94B |
| Revenue Growth % | 4.94% | 16.37% | 215.65% | 4.45% | 8.52% | 3.7% | 8.17% | 26.56% | 11.26% | 8.84% |
| Medical Costs & Claims | 27.72B | 32.32B | 128.49B | 136.19B | 151.12B | 157.02B | 170.09B | 221.16B | 248.97B | 252.09B |
| Medical Cost Ratio % | 66.3% | 66.44% | 83.67% | 84.91% | 86.81% | 86.98% | 87.11% | 89.49% | 90.55% | 90.7% |
| Gross Profit | 14.09B▲ 0% | 16.33B▲ 15.9% | 25.08B▲ 53.6% | 24.21B▼ 3.5% | 22.95B▼ 5.2% | 23.5B▲ 2.4% | 25.18B▲ 7.1% | 25.96B▲ 3.1% | 25.99B▲ 0.1% | 25.85B▲ 0% |
| Gross Margin % | 33.7% | 33.56% | 16.33% | 15.09% | 13.19% | 13.02% | 12.89% | 10.51% | 9.45% | 9.3% |
| Gross Profit Growth % | 8.12% | 15.92% | 53.59% | -3.48% | -5.19% | 2.39% | 7.14% | 3.13% | 0.08% | - |
| Operating Expenses | 10.14B | 12.17B | 17B | 16.05B | 15.01B | 15.05B | 16.64B | 16.55B | 16.86B | 16.33B |
| OpEx / Revenue % | 24.27% | 25.01% | 11.07% | 10.01% | 8.62% | 8.34% | 8.52% | 6.7% | 6.13% | 5.88% |
| Depreciation & Amortization | 250M | 356M | 2.77B | 1.8B | 1.8B | 1.86B | 1.81B | 1.75B | 2.63B | 2.61B |
| Combined Ratio % | 90.57% | 91.45% | 94.74% | 94.92% | 95.44% | 95.32% | 95.63% | 96.19% | 96.68% | 96.58% |
| Operating Income | 3.94B▲ 0% | 4.16B▲ 5.5% | 8.08B▲ 94.2% | 8.15B▲ 0.9% | 7.94B▼ 2.6% | 8.45B▲ 6.4% | 8.54B▲ 1.0% | 9.42B▲ 10.3% | 9.13B▼ 3.1% | 9.52B▲ 0% |
| Operating Margin % | 9.43% | 8.55% | 5.26% | 5.08% | 4.56% | 4.68% | 4.37% | 3.81% | 3.32% | 3.42% |
| Operating Income Growth % | 27.66% | 5.53% | 94.16% | 0.94% | -2.6% | 6.41% | 1.02% | 10.32% | -3.06% | - |
| EBITDA | 4.19B | 4.52B | 10.84B | 9.96B | 9.74B | 10.31B | 10.35B | 11.17B | 11.76B | 12.13B |
| EBITDA Margin % | 10.03% | 9.28% | 7.06% | 6.21% | 5.6% | 5.71% | 5.3% | 4.52% | 4.28% | 4.36% |
| Interest Expense | 252M | 498M | 1.68B | 1.44B | 1.21B | 1.23B | 1.45B | 1.44B | 1.38B | 1.38B |
| Non-Operating Income | -184M | -704M | -738M | -412M | -221M | -129M | -498M | -275M | 155M | 194M |
| Pretax Income | 3.61B▲ 0% | 3.58B▼ 0.7% | 6.57B▲ 83.5% | 10.87B▲ 65.4% | 6.79B▼ 37.5% | 8.4B▲ 23.7% | 5.51B▼ 34.3% | 5.27B▼ 4.4% | 7.59B▲ 44.1% | 8.21B▲ 0% |
| Pretax Margin % | 8.63% | 7.36% | 4.28% | 6.78% | 3.9% | 4.65% | 2.82% | 2.13% | 2.76% | 2.96% |
| Income Tax | 1.37B | 935M | 1.45B | 2.38B | 1.37B | 1.61B | 141M | 1.49B | 1.34B | 1.51B |
| Effective Tax Rate % | 38.1% | 26.11% | 22.07% | 21.89% | 20.18% | 19.23% | 2.56% | 28.3% | 17.71% | 18.44% |
| Net Income | 2.24B▲ 0% | 2.64B▲ 17.9% | 5.1B▲ 93.6% | 8.46B▲ 65.7% | 5.37B▼ 36.5% | 6.7B▲ 24.8% | 5.16B▼ 23.0% | 3.43B▼ 33.5% | 5.96B▲ 73.5% | 6.29B▲ 0% |
| Net Margin % | 5.35% | 5.42% | 3.32% | 5.27% | 3.08% | 3.71% | 2.64% | 1.39% | 2.17% | 2.26% |
| Net Income Growth % | 19.82% | 17.88% | 93.55% | 65.71% | -36.51% | 24.84% | -22.97% | -33.5% | 73.47% | 24.91% |
| EPS (Diluted) | 9.17▲ 0% | 10.54▲ 14.9% | 13.44▲ 27.5% | 22.96▲ 70.8% | 15.75▼ 31.4% | 21.41▲ 35.9% | 17.39▼ 18.8% | 12.12▼ 30.3% | 22.17▲ 82.9% | 23.80▲ 0% |
| EPS Growth % | 27.54% | 14.94% | 27.51% | 70.83% | -31.4% | 35.94% | -18.78% | -30.3% | 82.92% | 30.56% |
| EPS (Basic) | 9.17 | 10.69 | 13.58 | 23.17 | 15.89 | 21.66 | 17.57 | 12.25 | 22.30 | - |
| Diluted Shares Outstanding | 243.97M | 246.65M | 379.82M | 368.39M | 340.97M | 313.06M | 296.88M | 283.22M | 265.95M | 264.22M |
CI Balance Sheet
Cigna Corporation (CI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 61.76B | 153.23B | 155.77B | 155.45B | 154.89B | 143.88B | 152.76B | 155.88B | 157.92B | 153.27B |
| Asset Growth % | 4.04% | 148.1% | 1.66% | -0.21% | -0.36% | -7.1% | 6.17% | 2.04% | 1.31% | 0.77% |
| Total Investment Assets | 28.62B | 28.97B | 22.43B | 24.53B | 19.32B | 17.14B | 18.91B | 15.79B | 18.47B | 4M |
| Long-Term Investments | 26.48B | 26.93B | 21.49B | 23.2B | 18.4B | 16.24B | 17.98B | 15.13B | 18.47B | 71.52B |
| Short-Term Investments | 2.14B | 2.04B | 937M | 1.33B | 920M | 905M | 925M | 665M | 0 | 812M |
| Total Current Assets | 9.31B | 20.43B | 29.84B | 27.8B | 36.13B | 30.12B | 37.35B | 48.87B | 47.81B | 43.03B |
| Cash & Equivalents | 2.97B | 3.85B | 4.62B | 10.18B | 5.08B | 5.92B | 7.82B | 7.55B | 7.68B | 7.04B |
| Receivables | 2.9B | 10.2B | 10.38B | 12B | 14.62B | 16.97B | 17.45B | 24.07B | 28.77B | 118.23B |
| Other Current Assets | 1.07B | 1.51B | 11.25B | 1.12B | 11.8B | 1.55B | 5.51B | 9.9B | 4.03B | 2.74B |
| Goodwill & Intangibles | 7.32B | 86.79B | 84.36B | 82.84B | 82.72B | 81.15B | 77.94B | 76.61B | 73.48B | 293.28B |
| Goodwill | 6.16B | 44.51B | 44.6B | 44.65B | 45.81B | 45.81B | 44.26B | 44.37B | 44.92B | 45.53B |
| Intangible Assets | 1.15B | 42.28B | 39.76B | 38.19B | 36.91B | 35.34B | 33.68B | 32.24B | 28.56B | 27.32B |
| PP&E (Net) | 756M | 1.28B | 1.75B | 1.74B | 1.66B | 1.3B | 877M | 828M | 3.65B | 3.7B |
| Other Assets | 17.89B | 17.8B | 18.32B | 19.87B | 15.97B | 15.07B | 18.61B | 14.44B | 14.5B | 14.78B |
| Total Liabilities | 47.97B | 112.15B | 110.39B | 105.06B | 107.7B | 98.98B | 106.41B | 114.64B | 116.05B | 110.82B |
| Total Debt | 5.44B | 42.48B | 38.04B | 33.56B | 34.27B | 31.55B | 30.93B | 31.97B | 31.46B | 30.9B |
| Net Debt | 2.47B | 38.62B | 33.42B | 23.38B | 29.18B | 25.63B | 23.11B | 24.42B | 23.79B | 23.86B |
| Long-Term Debt | 5.19B | 39.49B | 31.83B | 29.51B | 31.1B | 28.03B | 28.09B | 28.9B | 30.87B | 29.37B |
| Short-Term Debt | 231M | 2.84B | 5.49B | 3.36B | 2.52B | 2.96B | 2.73B | 2.99B | 592M | 1.53B |
| Total Current Liabilities | 11.01B | 31.89B | 40.14B | 36.02B | 43.57B | 41.23B | 48.72B | 57.98B | 56.34B | 52.61B |
| Accounts Payable | 489M | 15.07B | 15.54B | 18.82B | 21.96B | 24.84B | 28.37B | 37.76B | 10.66B | 9.88B |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.57B | 6.8B | 13.05B | 5.31B | 11.74B | 5.41B | 9.73B | 10.7B | 45.09B | 41.2B |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 1000K | 1000K | 1000K | 27.77B |
| Other Liabilities | 31.79B | 40.74B | 37.9B | 39.01B | 32.57B | 29.46B | 22.37B | 20.75B | 21.69B | 22B |
| Total Equity | 13.78B▲ 0% | 41.07B▲ 198.0% | 45.38B▲ 10.5% | 50.39B▲ 11.0% | 47.18B▼ 6.4% | 44.95B▼ 4.7% | 46.35B▲ 3.1% | 41.24B▼ 11.0% | 41.87B▲ 1.5% | 42.44B▲ 0% |
| Equity Growth % | -0.01% | 197.97% | 10.49% | 11.03% | -6.35% | -4.73% | 3.11% | -11.02% | 1.53% | 3.24% |
| Shareholders Equity | 13.73B | 41.03B | 45.34B | 50.32B | 47.11B | 44.87B | 46.22B | 41.03B | 41.71B | 42.21B |
| Minority Interest | 49M | 44M | 41M | 65M | 72M | 79M | 128M | 210M | 161M | 232M |
| Retained Earnings | 15.82B | 15.09B | 20.16B | 28.57B | 32.59B | 37.87B | 41.65B | 43.52B | 47.87B | 49.11B |
| Common Stock | 74M | 4M | 4M | 4M | 4M | 4M | 4M | 4M | 4M | 4M |
| Accumulated OCI | -1.08B | -1.71B | -941M | -861M | -884M | -1.4B | -1.86B | -2.34B | -2.81B | -3.6B |
| Return on Equity (ROE) | 16.23% | 9.61% | 11.81% | 17.66% | 11.01% | 14.55% | 11.31% | 7.84% | 14.33% | 15.08% |
| Return on Assets (ROA) | 3.69% | 2.45% | 3.3% | 5.44% | 3.46% | 4.49% | 3.48% | 2.23% | 3.8% | 4.05% |
| Equity / Assets | 22.32% | 26.8% | 29.13% | 32.41% | 30.46% | 31.24% | 30.34% | 26.46% | 26.52% | 27.69% |
| Debt / Equity | 0.39x | 1.03x | 0.84x | 0.67x | 0.73x | 0.70x | 0.67x | 0.78x | 0.75x | 0.75x |
| Book Value per Share | 56.50 | 166.52 | 119.48 | 136.77 | 138.38 | 143.58 | 156.13 | 145.62 | 157.45 | 160.63 |
| Tangible BV per Share | 26.51 | -185.34 | -102.64 | -88.10 | -104.23 | -115.63 | -106.40 | -124.89 | -118.86 | -115.09 |
CI Cash Flow Statement
Cigna Corporation (CI) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 4.09B | 3.77B | 9.48B | 10.35B | 7.19B | 8.66B | 11.81B | 10.36B | 9.6B | 9.6B |
| Operating CF Growth % | 1.49% | -7.73% | 151.59% | 9.12% | -30.52% | 20.37% | 36.47% | -12.27% | -7.35% | 6495.62% |
| Operating CF / Revenue % | 9.77% | 7.75% | 6.18% | 6.45% | 4.13% | 4.8% | 6.05% | 4.19% | 3.49% | 3.45% |
| Net Income | 2.23B | 2.65B | 5.12B | 8.49B | 5.42B | 6.78B | 5.37B | 3.78B | 6.29B | 6.29B |
| Depreciation & Amortization | 566M | 695M | 3.65B | 2.8B | 2.92B | 2.94B | 3.04B | 2.77B | 2.77B | 2.75B |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 242M | -101M | -313M | -386M | -216M | -472M | -1.66B | -95M | 326M | 482M |
| Other Non-Cash Items | 281M | 81M | -175M | -4.15B | -57M | -1.18B | 1.58B | 2.71B | 11M | 81M |
| Working Capital Changes | 765M | 449M | 1.2B | 3.6B | -879M | 584M | 3.49B | 1.19B | 201M | -1.14B |
| Cash from Investing | -1.7B | -26.38B | -734M | 2.98B | -3.61B | 3.1B | -5.17B | -2.1B | -4.41B | -6.24B |
| Capital Expenditures | -471M | -528M | -1.05B | -1.09B | -1.15B | -1.29B | -1.57B | -1.41B | -1.21B | -1.15B |
| Acquisitions | -209M | -24.45B | -153M | 5.45B | -1.89B | 4.83B | -434M | 390M | -597M | 1.75B |
| Purchase of Investments | -6.69B | -6.83B | -6.04B | -6.69B | -6.11B | -4.32B | -5.54B | -2.69B | 0 | -3.23B |
| Sale/Maturity of Investments | 5.76B | 5.54B | 6.62B | 5.38B | 5.59B | 4.11B | 2.64B | 2.45B | 884M | 2.06B |
| Other Investing | -95M | -109M | -119M | -71M | -50M | -233M | -264M | -838M | -3.48B | -5.67B |
| Cash from Financing | -2.65B | 23.52B | -7.19B | -8.53B | -8.21B | -11.24B | -4.29B | -7.65B | -6.42B | -3.88B |
| Dividends Paid | 0 | 0 | -15M | -15M | -1.34B | -1.38B | -1.45B | -1.57B | -1.61B | -1.62B |
| Share Repurchases | -2.73B | -342M | -1.99B | -4.04B | -7.74B | -7.61B | -2.28B | -7.03B | -3.62B | -2.11B |
| Stock Issued | 131M | 68M | 224M | 376M | 326M | 389M | 187M | 305M | 203M | 191M |
| Debt Issuance (Net) | 1000K | 1000K | -1000K | -1000K | 1000K | -1000K | -1000K | 1000K | -1000K | 0 |
| Other Financing | -468M | -423M | -237M | -328M | -112M | -79M | -469M | -411M | -726M | -705M |
| Net Change in Cash | -213M▲ 0% | 883M▲ 514.6% | 1.56B▲ 76.2% | 4.83B▲ 210.7% | -4.7B▼ 197.2% | 428M▲ 109.1% | 2.36B▲ 451.6% | 594M▼ 74.8% | 126M▼ 78.8% | -1.3B▲ 0% |
| Exchange Rate Effect | 55M | -24M | -8M | 41M | -65M | -86M | 16M | -20M | 1.35B | 11M |
| Cash at Beginning | 3.19B | 2.97B | 3.85B | 5.41B | 10.24B | 5.55B | 5.98B | 8.34B | 7.55B | 7.74B |
| Cash at End | 2.97B | 3.85B | 5.41B | 10.24B | 5.55B | 5.98B | 8.34B | 8.93B | 7.68B | 7.08B |
| Free Cash Flow | 3.62B▲ 0% | 3.24B▼ 10.3% | 8.44B▲ 160.2% | 9.26B▲ 9.7% | 6.04B▼ 34.8% | 7.36B▲ 21.9% | 10.24B▲ 39.1% | 8.96B▼ 12.5% | 8.39B▼ 6.3% | 7.66B▲ 0% |
| FCF Growth % | 1.4% | -10.32% | 160.18% | 9.73% | -34.78% | 21.93% | 39.11% | -12.53% | -6.34% | 27.45% |
| FCF Margin % | 8.65% | 6.66% | 5.49% | 5.77% | 3.47% | 4.08% | 5.24% | 3.62% | 3.05% | 2.76% |
| FCF per Share | 14.82 | 13.14 | 22.21 | 25.13 | 17.71 | 23.51 | 34.49 | 31.63 | 31.54 | 31.54 |
CI Key Ratios
Cigna Corporation (CI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Combined Ratio | 90.57% | 91.45% | 94.74% | 94.92% | 95.44% | 95.32% | 95.63% | 96.19% | 96.68% | 96.58% |
| Medical Cost Ratio | 66.3% | 66.44% | 83.67% | 84.91% | 86.81% | 86.98% | 87.11% | 89.49% | 90.55% | 90.7% |
| Return on Equity (ROE) | 16.23% | 9.61% | 11.81% | 17.66% | 11.01% | 14.55% | 11.31% | 7.84% | 14.33% | 15.08% |
| Return on Assets (ROA) | 3.69% | 2.45% | 3.3% | 5.44% | 3.46% | 4.49% | 3.48% | 2.23% | 3.8% | 4.05% |
| Equity / Assets | 22.32% | 26.8% | 29.13% | 32.41% | 30.46% | 31.24% | 30.34% | 26.46% | 26.52% | 27.69% |
| Book Value / Share | 56.5 | 166.52 | 119.48 | 136.77 | 138.38 | 143.58 | 156.13 | 145.62 | 157.45 | 160.63 |
| Debt / Equity | 0.39x | 1.03x | 0.84x | 0.67x | 0.73x | 0.70x | 0.67x | 0.78x | 0.75x | 0.75x |
| Revenue Growth | 4.94% | 16.37% | 215.65% | 4.45% | 8.52% | 3.7% | 8.17% | 26.56% | 11.26% | 8.84% |
CI SEC Filings & Documents
Cigna Corporation (CI) SEC filings — annual & quarterly reports (10-K, 10-Q)
CI Frequently Asked Questions
Cigna Corporation (CI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cigna Corporation (CI) grew revenue by 11.3% over the past year. This is steady growth.
Yes, Cigna Corporation (CI) is profitable, generating $6.29B in net income for fiscal year 2025 (2.2% net margin).
Dividend & Returns
Yes, Cigna Corporation (CI) pays a dividend with a yield of 2.20%. This makes it attractive for income-focused investors.
Cigna Corporation (CI) has a return on equity (ROE) of 14.3%. This is reasonable for most industries.
Industry Metrics
Cigna Corporation (CI) has a combined ratio of 96.7%. A ratio below 100% indicates underwriting profitability.
Explore More CI
Cigna Corporation (CI) financial analysis — history, returns, DCA and operating performance tools
Full CI Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates